Here are 1-3 brief analogies for Pasithea Therapeutics (KTTA):

• One Medical for advanced depression treatments
• Warby Parker for psychiatric solutions

• Biotechnology Research and Development: Pasithea Therapeutics engages in the research and discovery of treatments for psychiatric and neurological disorders.
• Ketamine Infusion Therapy: The company operates anti-depression clinics to administer intravenous infusions of ketamine for treatment.
• Business Support Services: Pasithea Therapeutics provides business support services to trained pharmacists involved in administering ketamine infusions.

Pasithea Therapeutics (KTTA) primarily serves individuals. Its major customers fall into the following categories:

• Patients seeking treatment for depression: Individuals diagnosed with major depressive disorder, treatment-resistant depression, or other mood disorders who are seeking advanced or alternative therapies offered through the company's anti-depression clinics.
• Individuals pursuing ketamine infusion therapy: Patients specifically interested in and eligible for intravenous ketamine as a treatment modality for their psychiatric conditions, administered in the company's clinics.

Dr. Tiago Reis Marques, Chief Executive Officer and Director

Dr. Marques has served as Pasithea Therapeutics' Chief Executive Officer and on its board of directors since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King's College London, a leading center for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on the mechanism of action of psychiatric medication and novel treatment targets. He has authored or co-authored over 100 scientific publications in peer-reviewed journals and co-authored international treatment guidelines.

Daniel Schneiderman, Chief Financial Officer and Principal Accounting Officer

Mr. Schneiderman has served as Pasithea Therapeutics' Chief Financial Officer since October 2022, having previously consulted for the company. He is an experienced finance executive with over 24 years of experience in capital markets and finance operations. Prior to joining Pasithea, he served as Chief Financial Officer of First Wave BioPharma, Inc. from January 2020 to February 2022, and as Chief Financial Officer of Biophytis SA from November 2018 to December 2019. He also held the role of Vice President of Finance, Controller, and Secretary of MetaStat, Inc. from February 2012 to August 2018. Earlier in his career, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners and an investment banking analyst at H.C. Wainwright & Co., Inc.

Professor Lawrence J. Steinman, M.D., Executive Chairman of the Board

Professor Steinman co-founded Pasithea Therapeutics in 2020. He is a professor of neurology and neurological sciences, pediatrics, and genetics at Stanford Medical School, where he leads a research team focused on the pathogenesis of autoimmune diseases. He was a senior author on a seminal 1992 Nature article which reported a key role of an integrin in brain inflammation, contributing to the development of the drug Tysabri. He received his doctoral degree from Harvard Medical School and completed a post-doctoral fellowship in chemical immunology at the Weizmann Institute of Science. He has been recognized with numerous honors and awards, including the John M. Dystel Prize and the Charcot Prize for Lifetime Achievement in MS research.

Graeme Currie, PhD, Chief Development Officer

Dr. Currie possesses over 30 years of drug development experience across both pharmaceutical and biotechnology companies. He has held senior leadership roles, including C-suite and senior management positions, at various public and privately held biotech organizations such as BioClin Therapeutics, Dynavax Technologies, Tolerion Inc., Regeneron Pharmaceuticals, Sepracor, Protein Design Labs, and Gilead Sciences. Dr. Currie has been involved in the development of 8 approved new drugs.

Alfred Novak, Independent Director

Mr. Novak has served on Pasithea Therapeutics' Board since September 2022. He brings broad operating experience, having previously held positions as a Chief Executive Officer and Chief Financial Officer. He has also served on the boards of several pharmaceutical and medical device companies, contributing extensive expertise in product development, regulatory approval, and commercial activities.

The key risks for Pasithea Therapeutics (symbol: KTTA) are primarily centered around its nature as a clinical-stage biotechnology company developing novel treatments.

1. Clinical Trial Failure and Regulatory Approval: As a clinical-stage biotechnology company, Pasithea Therapeutics' success is heavily reliant on the successful outcome of its ongoing and future clinical trials for drug candidates such as PAS-004 and PAS-003. Unfavorable clinical trial results, delays in trials, or the inability to secure regulatory approval for their treatments would significantly impede the company's ability to bring products to market. The durability of the company's intellectual property is entirely dependent on successful clinical trials, regulatory approvals, and commercialization, which are highly uncertain.

2. Funding and Financial Viability: Pasithea Therapeutics is a pre-revenue company with a high cash burn rate, indicating it expends significant capital on research and development without corresponding revenue generation. The company faces ongoing challenges in securing additional funding, which poses a risk of insolvency or substantial dilution for existing shareholders. Public offerings, including a recent $60 million deal, highlight this reliance on external funding and have raised concerns about dilution risks. Shareholders have already experienced substantial dilution in the past year.

3. Nasdaq Delisting Risk: Pasithea Therapeutics has received a Nasdaq bid-price deficiency notice due to its shares trading below the required $1.00 minimum for 30 consecutive business days. The company has a limited timeframe to regain compliance with Nasdaq's listing rules, typically by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days. Failure to meet this requirement could lead to the delisting of its common stock, which can negatively impact investor confidence and access to capital.

The increasing development and potential regulatory approval of other psychedelic-assisted psychotherapies (e.g., psilocybin, MDMA) for depression and related mental health conditions. As these therapies progress through clinical trials and gain regulatory acceptance, they could present a direct alternative or even preferred treatment option for patients currently seeking or considering ketamine, thereby creating significant competition for Pasithea's planned clinic operations.

• The global ketamine clinic market was valued at approximately USD 1.52 billion in 2025 and is projected to reach approximately USD 3.35 billion by 2034.
• In the United States, the ketamine clinic market size was estimated at USD 457.31 million in 2024 and is projected to grow to around USD 1,121.83 million by 2034.

• The global neuropsychiatric disorders treatment market was estimated to be valued at USD 76.21 billion in 2025 and is expected to reach USD 101.64 billion by 2032. North America is projected to lead this global market.

Pasithea Therapeutics Corp. (KTTA) is anticipated to drive future revenue growth over the next two to three years through the following key initiatives:

1. Expansion of Ketamine Clinic Network: The company plans to expand its network of both mobile and in-person intravenous (IV) ketamine infusion therapy clinics. This expansion includes increasing its presence in the United States, such as Florida, Nevada, New York, and California, as well as in the United Kingdom, specifically London. This strategy aims to enhance patient access and broaden the company's market reach for its ketamine-based treatments for psychiatric conditions.
2. Diversification of Clinic Treatment Offerings: Pasithea Therapeutics is actively expanding the range of treatments offered within its clinics beyond solely IV ketamine. This diversification includes the introduction of other psychiatric therapies, such as repeated transcranial magnetic stimulation (rTMS) and pharmacy services. By offering a wider array of treatments, the company seeks to attract a more diverse patient population and generate additional revenue streams.
3. Advancement of PAS-004 for Neurofibromatosis Type 1 (NF1-PN): The company's lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor, is currently in Phase 1/1b clinical trials for adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. Pasithea expects to present further efficacy, safety, tolerability, and pharmacokinetic data for this program in the second half of 2026. Successful progression through these clinical trials and potential commercialization could become a significant future revenue driver.
4. Advancement of PAS-004 for Advanced Cancer: PAS-004 is also undergoing Phase 1 clinical trials for advanced cancer patients with MAPK pathway-driven tumors. The company anticipates presenting longer-term follow-up data from these trials in the second quarter of 2026. Positive outcomes in these studies could lead to the development and commercialization of PAS-004 for this indication, opening another substantial market for the drug and contributing to future revenue.

Share Repurchases

• In July 2023, Pasithea Therapeutics authorized an Equity Buyback program to repurchase up to 5,714,285 shares for $4 million at a price of $0.70 per share, with the tender offer expiring on September 8, 2023.

Share Issuance

• Pasithea Therapeutics closed a public offering in December 2025, issuing 80,000,000 common shares (or pre-funded warrants) at $0.75 per share, which generated gross proceeds of approximately $60 million.
• In May 2025, the company completed a public offering of 3,571,428 shares of common stock (or pre-funded warrants) and accompanying Series C and D warrants, resulting in total gross proceeds of $5.0 million from the offering itself, plus an additional $1.3 million from the exercise of Series D warrants, for aggregate gross proceeds of approximately $6.3 million.
• In September 2024, Pasithea raised approximately $4.5 million through a private placement by issuing pre-funded warrants and additional warrants.
• A 1:20 reverse stock split became effective on January 2, 2024, which reduced the number of outstanding shares and the authorized shares to 100,000,000.

Inbound Investments

• The $60 million public offering in December 2025 was notably led by healthcare-dedicated investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management.
• In November 2025, Pasithea received a Hoffman ALS Clinical Trial Award grant of approximately $1 million from the ALS Association to support a Phase 1 study of PAS-004 in ALS patients.
• The company raised approximately $4.5 million through a private placement in September 2024.

Outbound Investments

• In June 2022, Pasithea acquired Alpha-5 Integrin, LLC, a privately held biotechnology company, leading to the acquisition of PAS-003. As part of this acquisition, the AlloMek Sellers received 135,000 shares of common stock, warrants to purchase 50,000 shares, and a cash payment of $1.05 million, along with rights to future milestone and earn-out payments.

Capital Expenditures

• Pasithea reported Net Capital Expenditures of -$0.1 million in fiscal year 2023 and $0.1 million in fiscal year 2022.
• During 2023, the company discontinued its support services to anti-depression clinics in the U.K. and New York, and closed its clinical operations in Los Angeles, disposing of related property.
• Capital expenditures are primarily focused on the research and development of therapeutic product candidates, including the manufacturing of GMP-compliant Phase 1 clinical supplies for PAS-004 in June 2023 and the development of a tablet formulation for PAS-004 in 2024. The company also opened its first clinical site for the FIH Phase 1 Dose Escalation Study of PAS-004 in February 2024.